MRNA およびサル免疫不全ウイルス感染 cd4 表面タンパク質発現の単一細胞定量⁺ T 細胞孤立したアカゲザルから

Executive Industry Relevance

Single-cell proteo-transcriptional profiling enables biopharma R&D to resolve heterogeneous infected cell populations and identify therapeutic targets with mechanistic precision. By linking viral gene expression to host protein and transcript levels at single-cell resolution, the method supports target validation and de-risks early discovery decisions. This approach enhances predictive confidence in host-pathogen interaction studies and informs portfolio prioritization for antiviral interventions.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by linking viral gene expression states to host cofactor profiles in infected cells.
• Operational Value: Provides quantitative protein and mRNA readouts that clarify biological mechanisms underlying productive versus non-productive infection.
• Strategic Value: Supports predictive confidence in target selection by revealing differentially expressed host factors associated with viral life cycle stages.

Screening & Assay Development

• Scientific Value: Generates standardized, multiplexed quantitative data from sorted single cells, enabling reproducible assay development for host-pathogen studies.
• Operational Value: Integrates FACS isolation with high-throughput qPCR to create a scalable workflow for linked protein-transcriptional profiling.
• Strategic Value: Facilitates screening readiness by producing multidimensional single-cell datasets that inform compound effect on infected cell phenotypes.

Translational & Preclinical Research

• Scientific Value: Reveals in vivo post-transcriptional gene regulation and viral RNA expression heterogeneity, supporting biomarker discovery in relevant disease models.
• Operational Value: Enables direct comparison of infected and uninfected cells from the same specimen to assess host response modulation.
• Strategic Value: Informs risk-adjusted advancement decisions by characterizing host-pathogen interactions at single-cell resolution in preclinical systems.

Pipeline & Workflow Integration

The method bridges discovery biology and preclinical validation by enabling mechanistic de-risking of antiviral targets through quantitative single-cell analysis of infected cell states.

• Discovery Biology: Supports hypothesis testing and pathway clarification by correlating viral gene expression with host surface protein and transcript levels in sorted cell subsets.
• Screening: Delivers assay-ready, reproducible quantitative outputs from multiplexed protein and mRNA measurement in single cells.
• Analytics: Provides normalized gene expression and protein quantification data that enable statistical comparison of infected versus uninfected conditions.
• Translational Research: Connects early discovery to preclinical continuity by identifying differentially expressed host genes and proteins in SIV-infected cells ex vivo.
• Enterprise Reuse: Establishes a reusable platform for linked proteo-transcriptional profiling applicable to any cell population defined by surface markers, host genes, or pathogen expression.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in host-pathogen interactions by providing quantitative, multimodal single-cell resolution of infected cell states.
• Operational Value: Ensures standardization and reproducibility through indexed flow cytometry coupled with controlled qPCR pre-amplification and detection.
• Strategic Value: Improves go/no-go decisions by enabling early identification of host cofactors and viral reservoirs with therapeutic relevance.
• Portfolio Impact: Supports risk-adjusted prioritization of antiviral targets based on validated mechanistic insights from primary infected cell analysis.

Implementation Considerations

• Requires expertise in flow cytometry, single-cell sorting, and multiplexed qPCR assay design and execution.
• Dependent on access to fluorescence-activated cell sorters, microfluidic qPCR platforms, and RNase-free molecular biology workspaces.
• Necessitates cross-team standardization between immunology, virology, and genomics for consistent sample preparation and data integration.
• Involves adaptation considerations when applying the method to different tissue sources or cell types beyond CD4+ T cells.
• Practical limitations include assay multiplexing capacity constrained by microfluidic chip design and the need for immediate cell lysis post-sort to preserve RNA integrity.

Biopharma FAQs